An open-label study of herbal topical medication (Psirelax) for patients with chronic plaque psoriasis

Psirelax is an herbal topical medication indicated for the treatment of patients with psoriasis. Its efficacy was determined in an open-label study in 22 patients (15 men, 7 women) with a mean age of 48.9±11.8 years suffering from chronic plaque psoriasis. The patients were treated by application of Psirelax twice a day for a period of 4 weeks. Clinical assessment was performed using the Psoriasis Area and Severity Index (PASI) and the Beer-Sheva Psoriasis Severity Score (BPSS). The results shows that Psirelax was well tolerated and there no local or systemic side effects. There was 59% reduction in PASI, from a mean of 5.9 ± 4.0 before treatment to 2.4 ± 2.4 after treatment (p<0.001). In 8 patients (36%) PASI decreased in more than 75% (PASI75). In 16 patients (73%) PASI decreased in more than 50% (PASI50). Application of Psirelax was associated with a decrease in disease severity, as assessed by the patients and physicians. It is concluded that Psirelax treatment was well tolerated in patients with chronic plaque psoriasis.